Symbol | Exchange | Currency |
|---|
Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Basic Materials, Oil & Gas and Industrials sectors led shares higher. At the close in NYSE, the...
Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Technology, Utilities and Telecoms sectors led shares higher. At the close in NYSE, the Dow...
Investing.com – U.S. stocks were mixed after the close on Thursday, as gains in the Telecoms, Oil & Gas and Utilities sectors led shares higher while losses in the Financials,...
Ferrer entered into a definitive agreement with Alexza Pharmaceuticals Inc (NASDAQ:ALXA), whereby Ferrer will acquire the company for $0.90 per share in cash, plus contingent value...
On Tuesday, shares of pharmaceutical company Alexza Pharmaceuticals (NASDAQ:ALXA) are soaring, up over 66% in afternoon trading after the company announced it has entered into a...
Alexza Pharmaceuticals (NASDAQ:ALXA) disclosed on 26 February that it had entered into a non-binding 8 March 2016 letter of intent (LOI) from Ferrer on 15 February to acquire all...
Alexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system conditions. The Company's product candidates are based on the Staccato system technology. Its product candidates in development include AZ-002, which contains alprazolam as an active pharmaceutical ingredient (API) is developed for the management of patients with acute repetitive seizures, and AZ-007, which contains zaleplon as API is developed for the treatment of insomnia in patients who have difficulty falling asleep, including those patients with middle of the night awakening having difficulty falling back asleep. Its product also includes ADASUVE, which contains loxapine as API is developed for the treatment of agitation associated with schizophrenia or bipolar disorder. It has initiated a Phase IIa proof-of-concept study for AZ-002 in patients with epilepsy and has completed Phase I testing for AZ-007.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | |||||
| Technical Indicators | |||||
| Summary |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 71.86 | 74.65 | 69.76 | -20.83 | -22.48% | 12.16M | NASDAQ | |||
| 95.45 | 98.64 | 95.30 | -1.22 | -1.26% | 21.66M | NASDAQ | |||
| 88.19 | 90.17 | 87.72 | +0.50 | +0.57% | 5.03M | NYSE | |||
| 0.4589 | 0.5001 | 0.445 | -0.6411 | -58.28% | 7.82M | NASDAQ | |||
| 60.62 | 61.65 | 60.62 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 42.14 | 44.05 | 41.84 | +0.09 | +0.21% | 2.72M | NASDAQ | |||
| 3.5201 | 3.65 | 3.37 | +0.1101 | +3.23% | 423.63K | NYSE | |||
| 1.085 | 1.16 | 1.08 | +0.045 | +4.33% | 728.39K | NASDAQ | |||
| 2.81 | 2.99 | 2.75 | 0.00 | 0.00% | 5.08K | NYSE | |||
| 4.004 | 4.09 | 3.99 | +0.014 | +0.35% | 1.91M | NYSE | |||
| 11.73 | 11.73 | 11.73 | 0.000 | 0.00% | 0.00 | OTC Markets | |||
| 7.32 | 7.32 | 7.32 | +0.020 | +0.27% | 5.00 | NASDAQ | |||
| 2.50 | 2.64 | 2.35 | +0.87 | +53.36% | 44.15M | NASDAQ | |||
| 2.00 | 2.12 | 2.00 | -0.04 | -1.96% | 8.29K | NYSE | |||
| 5.67 | 5.95 | 5.53 | 0.00 | 0.00% | 0.00 | NASDAQ |